
COPENHAGEN, July 29 (Reuters) - Obesity drugmaker Novo Nordisk NOVOb.CO warned on Tuesday that full-year sales and operating proft would grow less than previously expected, marking its second forecast cut of 2025.
The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly LLY.N. Novo shares have fallen sharply over the past year.